Brief: Neuraxis Wins First FDA Nod for FD Pain Treatment
24/10/2025 13:05
Oct 24 (Reuters) - Neuraxis Inc NRXS.A: NEURAXIS AWARDED FIRST EVER FDA CLEARANCE FOR THE TREATMENT OF PAIN IN FUNCTIONAL DYSPEPSIA (FD) WITH ASSOCIATED NAUSEA SYMPTOMS IN THE ADULT PATIENT POPULATION Source text: ID:nGNX4Zwsdl Further company coverage: NRXS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuraxis
See all newsBrief: Neuraxis Inc Expects Net Sales Of About $1.6 Million For Three Months Ended March 31, 2026
Brief: Neuraxis Reports Strong Fourth Quarter And Full Year 2025 Financial Results
Brief: Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access To More Patients With Functional Abdominal Pain
Brief: Neuraxis Wins First FDA Nod for FD Pain Treatment
Brief: Neuraxis Terminates License Agreement With Masimo